Mark A. Stacy
Affiliations: |
Google:
"Mark Stacy"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Stacy M, Sajatovic M, Kane JM, et al. (2019) Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. Movement Disorders : Official Journal of the Movement Disorder Society |
| Black KJ, Nasrallah H, Isaacson S, et al. (2019) Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. Cns Spectrums. 1-2 |
| Black KJ, Nasrallah H, Isaacson S, et al. (2018) Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. Cns Spectrums. 23: 402-413 |
| Chou KL, Stacy M, Simuni T, et al. (2018) The spectrum of "off" in Parkinson's disease: What have we learned over 40 years? Parkinsonism & Related Disorders |
| Goetz CG, Stebbins GT, Chung KA, et al. (2017) Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Movement Disorders : Official Journal of the Movement Disorder Society |
| Hickey PT, Kuchibhatla M, Scott B, et al. (2017) Dopamine Transporter Imaging has no Impact on Functional Outcomes in de Novo Probable Parkinson's Disease. Journal of Parkinson's Disease |
| Hickey P, Stacy M. (2016) Deep brain stimulation: a paradigm shifting approach to treat Parkinson's disease Frontiers in Neuroscience. 10: 173-173 |
| Cooney JW, Stacy M. (2016) Neuropsychiatric Issues in Parkinson's Disease. Current Neurology and Neuroscience Reports. 16: 49 |
| Park A, Stacy M. (2015) Disease-Modifying Drugs in Parkinson's Disease. Drugs |
| Warren Olanow C, Bartus RT, Baumann TL, et al. (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Annals of Neurology. 78: 248-57 |